NEW YORK, Oct 12 – Illumina reported Thursday third-quarter net losses of $3.9 million, or 15 cents a share, on a pro forma basis, compared with a net loss of $1.5 million, or 11 cents a share in the year ago period.

Consensus estimates forecast net losses of 20 cents a share, based on two analysts surveyed by First Call/Thomson Financial.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.